GRI Bio Inc. (GRI) - Total Liabilities
Based on the latest financial reports, GRI Bio Inc. (GRI) has total liabilities worth $794.00K USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
GRI Bio Inc. - Total Liabilities Trend (2018–2025)
This chart illustrates how GRI Bio Inc.'s total liabilities have evolved over time, based on quarterly financial data. See GRI Bio Inc. (GRI) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
GRI Bio Inc. Competitors by Total Liabilities
The table below lists competitors of GRI Bio Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DSJ Keep Learning Limited
NSE:KEEPLEARN
|
India | Rs44.75 Million |
|
Weaccess Group SA
PA:MLWEA
|
France | €1.16 Million |
|
BPH Global Ltd
AU:BP8
|
Australia | AU$2.01 Million |
|
TCI Finance Limited
NSE:TCIFINANCE
|
India | Rs828.64 Million |
|
Usha Resources Ltd
V:USHA
|
Canada | CA$691.37K |
|
Genesis Resources Ltd
AU:GES
|
Australia | AU$22.73 Million |
|
Millennium Silver Corp
V:MSC
|
Canada | CA$513.83K |
|
Pragma Inkaso S.A.
WAR:PRI
|
Poland | zł12.10 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down GRI Bio Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GRI Bio Inc. market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GRI Bio Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GRI Bio Inc. (2018–2025)
The table below shows the annual total liabilities of GRI Bio Inc. from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.66 Million | +55.71% |
| 2024-12-31 | $1.71 Million | -36.71% |
| 2023-12-31 | $2.70 Million | +34.31% |
| 2022-12-31 | $2.01 Million | -59.37% |
| 2021-12-31 | $4.94 Million | +105.15% |
| 2020-12-31 | $2.41 Million | +126.87% |
| 2019-12-31 | $1.06 Million | +118.36% |
| 2018-12-31 | $486.29K | -- |
About GRI Bio Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung … Read more